name	description	sequence
P00863_C03	crenezumab	GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCACCTTCAGCAGCTACGGCATGAGCTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGCTGGTGGCCAGCATCAACAGCAACGGCGGCAGCACCTACTACCCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACAGCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGCGGCGACTACTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
P00863_C09	dinutuximab	GAGGTGCAGCTGCTGCAGAGCGGCCCCGAGCTGGAGAAGCCCGGCGCCAGCGTGATGATCAGCTGCAAGGCCAGCGGCAGCAGCTTCACCGGCTACAACATGAACTGGGTGAGGCAGAACATCGGCAAGAGCCTGGAGTGGATCGGCGCCATCGACCCCTACTACGGCGGCACCAGCTACAACCAGAAGTTCAAGGGCAGGGCCACCCTGACCGTGGACAAGAGCAGCAGCACCGCCTACATGCACCTGAAGAGCCTGACCAGCGAGGACAGCGCCGTGTACTACTGCGTGAGCGGCATGGAGTACTGGGGCCAGGGCACCAGCGTGACCGTGAGCAGC
P01274_H01	nivolumab	CAGGTGCAGCTGGTGGAGAGCGGCGGCGGCGTGGTGCAGCCCGGCAGGAGCCTGAGGCTGGACTGCAAGGCCAGCGGCATCACCTTCAGCAACAGCGGCATGCACTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGGCCGTGATCTGGTACGACGGCAGCAAGAGGTACTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTTCCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCACCAACGACGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P01274_H11	ozanezumab	CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCTACACCTTCACCAGCTACTGGATGCACTGGGTGAGGCAGGCCCCCGGCCAGGGCCTGGAGTGGATCGGCAACATCAACCCCAGCAACGGCGGCACCAACTACAACGAGAAGTTCAAGAGCAAGGCCACCATGACCAGGGACACCAGCACCAGCACCGCCTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGAGCTGATGCAGGGCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P00863_C04	dacetuzumab	GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTACAGCTTCACCGGCTACTACATCCACTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGGCCAGGGTGATCCCCAACGCCGGCGGCACCAGCTACAACCAGAAGTTCAAGGGCAGGTTCACCCTGAGCGTGGACAACAGCAAGAACACCGCCTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGGAGGGCATCTACTGGTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P00125_B02	bimagrumab	CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCTACACCTTCACCAGCAGCTACATCAACTGGGTGAGGCAGGCCCCCGGCCAGGGCCTGGAGTGGATGGGCACCATCAACCCCGTGAGCGGCAGCACCAGCTACGCCCAGAAGTTCCAGGGCAGGGTGACCATGACCAGGGACACCAGCATCAGCACCGCCTACATGGAGCTGAGCAGGCTGAGGAGCGACGACACCGCCGTGTACTACTGCGCCAGGGGCGGCTGGTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P00863_B06	briakinumab	CAGGTGCAGCTGGTGGAGAGCGGCGGCGGCGTGGTGCAGCCCGGCAGGAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCACCTTCAGCAGCTACGGCATGCACTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGGCCTTCATCAGGTACGACGGCAGCAACAAGTACTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCAAGACCCACGGCAGCCACGACAACTGGGGCCAGGGCACCATGGTGACCGTGAGCAGC
P00863_C02	codrituzumab	CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCTACACCTTCACCGACTACGAGATGCACTGGGTGAGGCAGGCCCCCGGCCAGGGCCTGGAGTGGATGGGCGCCCTGGACCCCAAGACCGGCGACACCGCCTACAGCCAGAAGTTCAAGGGCAGGGTGACCCTGACCGCCGACAAGAGCACCAGCACCGCCTACATGGAGCTGAGCAGCCTGACCAGCGAGGACACCGCCGTGTACTACTGCACCAGGTTCTACAGCTACACCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P01274_D05	emibetuzumab	CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCTACACCTTCACCGACTACTACATGCACTGGGTGAGGCAGGCCCCCGGCCAGGGCCTGGAGTGGATGGGCAGGGTGAACCCCAACAGGAGGGGCACCACCTACAACCAGAAGTTCGAGGGCAGGGTGACCATGACCACCGACACCAGCACCAGCACCGCCTACATGGAGCTGAGGAGCCTGAGGAGCGACGACACCGCCGTGTACTACTGCGCCAGGGCCAACTGGCTGGACTACTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
P01274_D09	evolocumab	GAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCTACACCCTGACCAGCTACGGCATCAGCTGGGTGAGGCAGGCCCCCGGCCAGGGCCTGGAGTGGATGGGCTGGGTGAGCTTCTACAACGGCAACACCAACTACGCCCAGAAGCTGCAGGGCAGGGGCACCATGACCACCGACCCCAGCACCAGCACCGCCTACATGGAGCTGAGGAGCCTGAGGAGCGACGACACCGCCGTGTACTACTGCGCCAGGGGCTACGGCATGGACGTGTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
P01274_F10	lampalizumab	GAGGTGCAGCTGGTGCAGAGCGGCCCCGAGCTGAAGAAGCCCGGCGCCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCTACACCTTCACCAACTACGGCATGAACTGGGTGAGGCAGGCCCCCGGCCAGGGCCTGGAGTGGATGGGCTGGATCAACACCTACACCGGCGAGACCACCTACGCCGACGACTTCAAGGGCAGGTTCGTGTTCAGCCTGGACACCAGCGTGAGCACCGCCTACCTGCAGATCAGCAGCCTGAAGGCCGAGGACACCGCCGTGTACTACTGCGAGAGGGAGGGCGGCGTGAACAACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P00483_D05	zanolimumab	CAGGTGCAGCTGCAGCAGTGGGGCGCCGGCCTGCTGAAGCCCAGCGAGACCCTGAGCCTGACCTGCGCCGTGTACGGCGGCAGCTTCAGCGGCTACTACTGGAGCTGGATCAGGCAGCCCCCCGGCAAGGGCCTGGAGTGGATCGGCGAGATCAACCACAGCGGCAGCACCAACTACAACCCCAGCCTGAAGAGCAGGGTGACCATCAGCGTGGACACCAGCAAGAACCAGTTCAGCCTGAAGCTGAGCAGCGTGACCGCCGCCGACACCGCCGTGTACTACTGCGCCAGGGTGATCAACTGGTTCGACCCCTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P00863_B07	brodalumab	CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCTACACCTTCACCAGGTACGGCATCAGCTGGGTGAGGCAGGCCCCCGGCCAGGGCCTGGAGTGGATGGGCTGGATCAGCACCTACAGCGGCAACACCAACTACGCCCAGAAGCTGCAGGGCAGGGTGACCATGACCACCGACACCAGCACCAGCACCGCCTACATGGAGCTGAGGAGCCTGAGGAGCGACGACACCGCCGTGTACTACTGCGCCAGGAGGCAGCTGTACTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P00863_C05	daclizumab	CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCAGCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCTACACCTTCACCAGCTACAGGATGCACTGGGTGAGGCAGGCCCCCGGCCAGGGCCTGGAGTGGATCGGCTACATCAACCCCAGCACCGGCTACACCGAGTACAACCAGAAGTTCAAGGACAAGGCCACCATCACCGCCGACGAGAGCACCAACACCGCCTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGGGCGGCGGCGTGTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P01274_D07	epratuzumab	CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCAGCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCTACACCTTCACCAGCTACTGGCTGCACTGGGTGAGGCAGGCCCCCGGCCAGGGCCTGGAGTGGATCGGCTACATCAACCCCAGGAACGACTACACCGAGTACAACCAGAACTTCAAGGACAAGGCCACCATCACCGCCGACGAGAGCACCAACACCGCCTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCTTCTACTTCTGCGCCAGGAGGGACATCACCACCTTCTACTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
P01274_E10	gemtuzumab	GAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCAGCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCTACACCATCACCGACAGCAACATCCACTGGGTGAGGCAGGCCCCCGGCCAGAGCCTGGAGTGGATCGGCTACATCTACCCCTACAACGGCGGCACCGACTACAACCAGAAGTTCAAGAACAGGGCCACCCTGACCGTGGACAACCCCACCAACACCGCCTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCTTCTACTACTGCGTGAACGGCAACCCCTGGCTGGCCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P01274_G01	lintuzumab	CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCAGCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCTACACCTTCACCGACTACAACATGCACTGGGTGAGGCAGGCCCCCGGCCAGGGCCTGGAGTGGATCGGCTACATCTACCCCTACAACGGCGGCACCGGCTACAACCAGAAGTTCAAGAGCAAGGCCACCATCACCGCCGACGAGAGCACCAACACCGCCTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGGGCAGGCCCGCCATGGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P01274_H10	otlertuzumab	GAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGAGAGCCTGAAGATCAGCTGCAAGGGCAGCGGCTACAGCTTCACCGGCTACAACATGAACTGGGTGAGGCAGATGCCCGGCAAGGGCCTGGAGTGGATGGGCAACATCGACCCCTACTACGGCGGCACCACCTACAACAGGAAGTTCAAGGGCCAGGTGACCATCAGCGCCGACAAGAGCATCAGCACCGCCTACCTGCAGTGGAGCAGCCTGAAGGCCAGCGACACCGCCATGTACTACTGCGCCAGGAGCGTGGGCCCCTTCGACAGCTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P00483_A02	panobacumab	GAGGAGCAGGTGGTGGAGAGCGGCGGCGGCTTCGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCACCTTCAGCCCCTACTGGATGCACTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGTGTGGGTGAGCAGGATCAACAGCGACGGCAGCACCTACTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAGGAACACCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGGACAGGTACTACGGCCCCGAGATGTGGGGCCAGGGCACCATGGTGACCGTGAGCAGC
P00483_A09	ponezumab	CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCTACTACACCGAGGCCTACTACATCCACTGGGTGAGGCAGGCCCCCGGCCAGGGCCTGGAGTGGATGGGCAGGATCGACCCCGCCACCGGCAACACCAAGTACGCCCCCAGGCTGCAGGACAGGGTGACCATGACCAGGGACACCAGCACCAGCACCGTGTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGCCTGTACAGCCTGCCCGTGTACTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
P00483_A10	radretumab	GAGGTGCAGCTGCTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCACCTTCAGCAGCTTCAGCATGAGCTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGAGCAGCATCAGCGGCAGCAGCGGCACCACCTACTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAAGCCCTTCCCCTACTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P00483_A11	ramucirumab	GAGGTGCAGCTGGTGCAGAGCGGCGGCGGCCTGGTGAAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCACCTTCAGCAGCTACAGCATGAACTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGAGCAGCATCAGCAGCAGCAGCAGCTACATCTACTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACAGCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGGTGACCGACGCCTTCGACATCTGGGGCCAGGGCACCATGGTGACCGTGAGCAGC
P00483_B01	reslizumab	GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGTGAGCGGCCTGAGCCTGACCAGCAACAGCGTGAACTGGATCAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGGGCCTGATCTGGAGCAACGGCGACACCGACTACAACAGCGCCATCAAGAGCAGGTTCACCATCAGCAGGGACACCAGCAAGAGCACCGTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGGAGTACTACGGCTACTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P00483_B06	sarilumab	GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCAGGAGCCTGAGGCTGAGCTGCGCCGCCAGCAGGTTCACCTTCGACGACTACGCCATGCACTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGAGCGGCATCAGCTGGAACAGCGGCAGGATCGGCTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCGAGAACAGCCTGTTCCTGCAGATGAACGGCCTGAGGGCCGAGGACACCGCCCTGTACTACTGCGCCAAGGGCAGGGACAGCTTCGACATCTGGGGCCAGGGCACCATGGTGACCGTGAGCAGC
P00483_B09	sifalimumab	CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCTACACCTTCACCAGCTACAGCATCAGCTGGGTGAGGCAGGCCCCCGGCCAGGGCCTGGAGTGGATGGGCTGGATCAGCGTGTACAACGGCAACACCAACTACGCCCAGAAGTTCCAGGGCAGGGTGACCATGACCACCGACACCAGCACCAGCACCGCCTACCTGGAGCTGAGGAGCCTGAGGAGCGACGACACCGCCGTGTACTACTGCGCCAGGGACCCCATCGCCGCCGGCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P00483_B11	simtuzumab	CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCTACGCCTTCACCTACTACCTGATCGAGTGGGTGAGGCAGGCCCCCGGCCAGGGCCTGGAGTGGATCGGCGTGATCAACCCCGGCAGCGGCGGCACCAACTACAACGAGAAGTTCAAGGGCAGGGCCACCATCACCGCCGACAAGAGCACCAGCACCGCCTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTTCTGCGCCAGGAACTGGATGAACTTCGACTACTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
P00483_C05	tildrakizumab	CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCTACATCTTCATCACCTACTGGATGACCTGGGTGAGGCAGGCCCCCGGCCAGGGCCTGGAGTGGATGGGCCAGATCTTCCCCGCCAGCGGCAGCGCCGACTACAACGAGAAGTTCGAGGGCAGGGTGACCATGACCACCGACACCAGCACCAGCACCGCCTACATGGAGCTGAGGAGCCTGAGGAGCGACGACACCGCCGTGTACTACTGCGCCAGGGGCGGCGGCGGCTTCGCCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P00125_A06	anifrolumab	GAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGAGAGCCTGAAGATCAGCTGCAAGGGCAGCGGCTACATCTTCACCAACTACTGGATCGCCTGGGTGAGGCAGATGCCCGGCAAGGGCCTGGAGAGCATGGGCATCATCTACCCCGGCGACAGCGACATCAGGTACAGCCCCAGCTTCCAGGGCCAGGTGACCATCAGCGCCGACAAGAGCATCACCACCGCCTACCTGCAGTGGAGCAGCCTGAAGGCCAGCGACACCGCCATGTACTACTGCGCCAGGCACGACATCGAGGGCTTCGACTACTGGGGCAGGGGCACCCTGGTGACCGTGAGCAGC
P00125_A09	basiliximab	CAGGTGCAGCTGCAGCAGAGCGGCACCGTGCTGGCCAGGCCCGGCGCCAGCGTGAAGATGAGCTGCAAGGCCAGCGGCTACAGCTTCACCAGGTACTGGATGCACTGGATCAAGCAGAGGCCCGGCCAGGGCCTGGAGTGGATCGGCGCCATCTACCCCGGCAACAGCGACACCAGCTACAACCAGAAGTTCGAGGGCAAGGCCAAGCTGACCGCCGTGACCAGCGCCAGCACCGCCTACATGGAGCTGAGCAGCCTGACCCACGAGGACAGCGCCGTGTACTACTGCAGCAGGGACTACGGCTACTACTTCGACTTCTGGGGCCAGGGCACCACCCTGACCGTGAGCAGC
P00863_B05	brentuximab	CAGATCCAGCTGCAGCAGAGCGGCCCCGAGGTGGTGAAGCCCGGCGCCAGCGTGAAGATCAGCTGCAAGGCCAGCGGCTACACCTTCACCGACTACTACATCACCTGGGTGAAGCAGAAGCCCGGCCAGGGCCTGGAGTGGATCGGCTGGATCTACCCCGGCAGCGGCAACACCAAGTACAACGAGAAGTTCAAGGGCAAGGCCACCCTGACCGTGGACACCAGCAGCAGCACCGCCTTCATGCAGCTGAGCAGCCTGACCAGCGAGGACACCGCCGTGTACTTCTGCGCCAACTACGGCAACTACTGGTTCGCCTACTGGGGCCAGGGCACCCAGGTGACCGTGAGCGCC
P00863_C06	dalotuzumab	CAGGTGCAGCTGCAGGAGAGCGGCCCCGGCCTGGTGAAGCCCAGCGAGACCCTGAGCCTGACCTGCACCGTGAGCGGCTACAGCATCACCGGCGGCTACCTGTGGAACTGGATCAGGCAGCCCCCCGGCAAGGGCCTGGAGTGGATCGGCTACATCAGCTACGACGGCACCAACAACTACAAGCCCAGCCTGAAGGACAGGGTGACCATCAGCAGGGACACCAGCAAGAACCAGTTCAGCCTGAAGCTGAGCAGCGTGACCGCCGCCGACACCGCCGTGTACTACTGCGCCAGGTACGGCAGGGTGTTCTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P01274_D08	etrolizumab	GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCTTCATCACCAACAACTACTGGGGCTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGGGCTACATCAGCTACAGCGGCAGCACCAGCTACAACCCCAGCCTGAAGAGCAGGTTCACCATCAGCAGGGACACCAGCAAGAACACCTTCTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGACCGGCAGCAGCGGCTACTTCGACTTCTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P01274_F03	guselkumab	GAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGAGAGCCTGAAGATCAGCTGCAAGGGCAGCGGCTACAGCTTCAGCAACTACTGGATCGGCTGGGTGAGGCAGATGCCCGGCAAGGGCCTGGAGTGGATGGGCATCATCGACCCCAGCAACAGCTACACCAGGTACAGCCCCAGCTTCCAGGGCCAGGTGACCATCAGCGCCGACAAGAGCATCAGCACCGCCTACCTGCAGTGGAGCAGCCTGAAGGCCAGCGACACCGCCATGTACTACTGCGCCAGGTGGTACTACAAGCCCTTCGACGTGTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P00483_A04	patritumab	CAGGTGCAGCTGCAGCAGTGGGGCGCCGGCCTGCTGAAGCCCAGCGAGACCCTGAGCCTGACCTGCGCCGTGTACGGCGGCAGCTTCAGCGGCTACTACTGGAGCTGGATCAGGCAGCCCCCCGGCAAGGGCCTGGAGTGGATCGGCGAGATCAACCACAGCGGCAGCACCAACTACAACCCCAGCCTGAAGAGCAGGGTGACCATCAGCGTGGAGACCAGCAAGAACCAGTTCAGCCTGAAGCTGAGCAGCGTGACCGCCGCCGACACCGCCGTGTACTACTGCGCCAGGGACAAGTGGACCTGGTACTTCGACCTGTGGGGCAGGGGCACCCTGGTGACCGTGAGCAGC
P00483_A08	polatuzumab	GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTACACCTTCAGCAGCTACTGGATCGAGTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGATCGGCGAGATCCTGCCCGGCGGCGGCGACACCAACTACAACGAGATCTTCAAGGGCAGGGCCACCTTCAGCGCCGACACCAGCAAGAACACCGCCTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCACCAGGAGGGTGCCCATCAGGCTGGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P00125_A01	abituzumab	CAGGTGCAGCTGCAGCAGAGCGGCGGCGAGCTGGCCAAGCCCGGCGCCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCTACACCTTCAGCAGCTTCTGGATGCACTGGGTGAGGCAGGCCCCCGGCCAGGGCCTGGAGTGGATCGGCTACATCAACCCCAGGAGCGGCTACACCGAGTACAACGAGATCTTCAGGGACAAGGCCACCATGACCACCGACACCAGCACCAGCACCGCCTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGCTTCCTGGGCAGGGGCGCCATGGACTACTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
P00125_A02	abrilumab	CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTGAGCTGCAAGGTGAGCGGCTACACCCTGAGCGACCTGAGCATCCACTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGATGGGCGGCTTCGACCCCCAGGACGGCGAGACCATCTACGCCCAGAAGTTCCAGGGCAGGGTGACCATGACCGAGGACACCAGCACCGACACCGCCTACATGGAGCTGAGCAGCCTGAAGAGCGAGGACACCGCCGTGTACTACTGCGCCACCGGCAGCAGCAGCAGCTGGTTCGACCCCTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P00125_A05	alirocumab	GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCACCTTCAACAACTACGCCATGAACTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGACTGGGTGAGCACCATCAGCGGCAGCGGCGGCACCACCAACTACGCCGACAGCGTGAAGGGCAGGTTCATCATCAGCAGGGACAGCAGCAAGCACACCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAAGGACAGCAACTGGGGCAACTTCGACCTGTGGGGCAGGGGCACCCTGGTGACCGTGAGCAGC
P00125_A07	atezolizumab	GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCACCTTCAGCGACAGCTGGATCCACTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGGCCTGGATCAGCCCCTACGGCGGCAGCACCTACTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCGCCGACACCAGCAAGAACACCGCCTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGAGGCACTGGCCCGGCGGCTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P00863_B03	blosozumab	CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTGAGCTGCAAGGTGAGCGGCTTCCCCATCAAGGACACCTTCCAGCACTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGATGGGCTGGAGCGACCCCGAGATCGGCGACACCGAGTACGCCAGCAAGTTCCAGGGCAGGGTGACCATGACCGAGGACACCAGCACCGACACCGCCTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCACCGGCGACACCACCTACAAGTTCGACTTCTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
P00863_B04	bococizumab	CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCTACACCTTCACCAGCTACTACATGCACTGGGTGAGGCAGGCCCCCGGCCAGGGCCTGGAGTGGATGGGCGAGATCAGCCCCTTCGGCGGCAGGACCAACTACAACGAGAAGTTCAAGAGCAGGGTGACCATGACCAGGGACACCAGCACCAGCACCGTGTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGGAGAGGCCCCTGTACGCCAGCGACCTGTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
P00863_B08	canakinumab	CAGGTGCAGCTGGTGGAGAGCGGCGGCGGCGTGGTGCAGCCCGGCAGGAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCACCTTCAGCGTGTACGGCATGAACTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGGCCATCATCTGGTACGACGGCGACAACCAGTACTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTACCTGCAGATGAACGGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGGACCTGAGGACCGGCCCCTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P00863_B10	certolizumab	GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTACGTGTTCACCGACTACGGCATGAACTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGATGGGCTGGATCAACACCTACATCGGCGAGCCCATCTACGCCGACAGCGTGAAGGGCAGGTTCACCTTCAGCCTGGACACCAGCAAGAGCACCGCCTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGGGCTACAGGAGCTACGCCATGGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P01274_E01	ficlatuzumab	CAGGTGCAGCTGGTGCAGCCCGGCGCCGAGGTGAAGAAGCCCGGCACCAGCGTGAAGCTGAGCTGCAAGGCCAGCGGCTACACCTTCACCACCTACTGGATGCACTGGGTGAGGCAGGCCCCCGGCCAGGGCCTGGAGTGGATCGGCGAGATCAACCCCACCAACGGCCACACCAACTACAACCAGAAGTTCCAGGGCAGGGCCACCCTGACCGTGGACAAGAGCACCAGCACCGCCTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGAACTACGTGGGCAGCATCTTCGACTACTGGGGCCAGGGCACCCTGCTGACCGTGAGCAGC
P01274_E04	foralumab	CAGGTGCAGCTGGTGGAGAGCGGCGGCGGCGTGGTGCAGCCCGGCAGGAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCAAGTTCAGCGGCTACGGCATGCACTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGGCCGTGATCTGGTACGACGGCAGCAAGAAGTACTACGTGGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGCAGATGGGCTACTGGCACTTCGACCTGTGGGGCAGGGGCACCCTGGTGACCGTGAGCAGC
P01274_F08	ipilimumab	CAGGTGCAGCTGGTGGAGAGCGGCGGCGGCGTGGTGCAGCCCGGCAGGAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCACCTTCAGCAGCTACACCATGCACTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGACCTTCATCAGCTACGACGGCAACAACAAGTACTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCATCTACTACTGCGCCAGGACCGGCTGGCTGGGCCCCTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P01274_F11	lebrikizumab	CAGGTGACCCTGAGGGAGAGCGGCCCCGCCCTGGTGAAGCCCACCCAGACCCTGACCCTGACCTGCACCGTGAGCGGCTTCAGCCTGAGCGCCTACAGCGTGAACTGGATCAGGCAGCCCCCCGGCAAGGCCCTGGAGTGGCTGGCCATGATCTGGGGCGACGGCAAGATCGTGTACAACAGCGCCCTGAAGAGCAGGCTGACCATCAGCAAGGACACCAGCAAGAACCAGGTGGTGCTGACCATGACCAACATGGACCCCGTGGACACCGCCACCTACTACTGCGCCGGCGACGGCTACTACCCCTACGCCATGGACAACTGGGGCCAGGGCAGCCTGGTGACCGTGAGCAGC
P01274_G03	lumiliximab	GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGCCAAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCAGGTTCACCTTCAACAACTACTACATGGACTGGGTGAGGCAGGCCCCCGGCCAGGGCCTGGAGTGGGTGAGCAGGATCAGCAGCAGCGGCGACCCCACCTGGTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGAGAACGCCAACAACACCCTGTTCCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGCCTGACCACCGGCAGCGACAGCTGGGGCCAGGGCGTGCTGGTGACCGTGAGCAGC
P00483_B04	robatumumab	GAGGTGCAGCTGGTGCAGAGCGGCGGCGGCCTGGTGAAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCACCTTCAGCAGCTTCGCCATGCACTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGATCAGCGTGATCGACACCAGGGGCGCCACCTACTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACAGCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGCTGGGCAACTTCTACTACGGCATGGACGTGTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
P00125_A08	bapineuzumab	GAGGTGCAGCTGCTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCACCTTCAGCAACTACGGCATGAGCTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGGCCAGCATCAGGAGCGGCGGCGGCAGGACCTACTACAGCGACAACGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGTGAGGTACGACCACTACAGCGGCAGCAGCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P00863_B09	carlumab	CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCAGCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCGGCACCTTCAGCAGCTACGGCATCAGCTGGGTGAGGCAGGCCCCCGGCCAGGGCCTGGAGTGGATGGGCGGCATCATCCCCATCTTCGGCACCGCCAACTACGCCCAGAAGTTCCAGGGCAGGGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGTACGACGGCATCTACGGCGAGCTGGACTTCTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P00863_B11	cetuximab	CAGGTGCAGCTGAAGCAGAGCGGCCCCGGCCTGGTGCAGCCCAGCCAGAGCCTGAGCATCACCTGCACCGTGAGCGGCTTCAGCCTGACCAACTACGGCGTGCACTGGGTGAGGCAGAGCCCCGGCAAGGGCCTGGAGTGGCTGGGCGTGATCTGGAGCGGCGGCAACACCGACTACAACACCCCCTTCACCAGCAGGCTGAGCATCAACAAGGACAACAGCAAGAGCCAGGTGTTCTTCAAGATGAACAGCCTGCAGAGCAACGACACCGCCATCTACTACTGCGCCAGGGCCCTGACCTACTACGACTACGAGTTCGCCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCGCC
P01274_D04	elotuzumab	GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCGACTTCAGCAGGTACTGGATGAGCTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGATCGGCGAGATCAACCCCGACAGCAGCACCATCAACTACGCCCCCAGCCTGAAGGACAAGTTCATCATCAGCAGGGACAACGCCAAGAACAGCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGCCCGACGGCAACTACTGGTACTTCGACGTGTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P01274_D10	farletuzumab	GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCGTGGTGCAGCCCGGCAGGAGCCTGAGGCTGAGCTGCAGCGCCAGCGGCTTCACCTTCAGCGGCTACGGCCTGAGCTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGGCCATGATCAGCAGCGGCGGCAGCTACACCTACTACGCCGACAGCGTGAAGGGCAGGTTCGCCATCAGCAGGGACAACGCCAAGAACACCCTGTTCCTGCAGATGGACAGCCTGAGGCCCGAGGACACCGGCGTGTACTTCTGCGCCAGGCACGGCGACGACCCCGCCTGGTTCGCCTACTGGGGCCAGGGCACCCCCGTGACCGTGAGCAGC
P01274_D11	fasinumab	CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTGAGCTGCAAGGTGAGCGGCTTCACCCTGACCGAGCTGAGCATCCACTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGATGGGCGGCTTCGACCCCGAGGACGGCGAGACCATCTACGCCCAGAAGTTCCAGGGCAGGGTGACCATGACCGAGGACACCAGCACCGACACCGCCTACATGGAGCTGACCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCAGCACCATCTTCGGCGTGGTGACCAACTTCGACAACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P01274_E08	ganitumab	CAGGTGCAGCTGCAGGAGAGCGGCCCCGGCCTGGTGAAGCCCAGCGGCACCCTGAGCCTGACCTGCGCCGTGAGCGGCGGCAGCATCAGCAGCAGCAACTGGTGGAGCTGGGTGAGGCAGCCCCCCGGCAAGGGCCTGGAGTGGATCGGCGAGATCTACCACAGCGGCAGCACCAACTACAACCCCAGCCTGAAGAGCAGGGTGACCATCAGCGTGGACAAGAGCAAGAACCAGTTCAGCCTGAAGCTGAGCAGCGTGACCGCCGCCGACACCGCCGTGTACTACTGCGCCAGGTGGACCGGCAGGACCGACGCCTTCGACATCTGGGGCCAGGGCACCATGGTGACCGTGAGCAGC
P01274_E12	girentuximab	GACGTGAAGCTGGTGGAGAGCGGCGGCGGCCTGGTGAAGCTGGGCGGCAGCCTGAAGCTGAGCTGCGCCGCCAGCGGCTTCACCTTCAGCAACTACTACATGAGCTGGGTGAGGCAGACCCCCGAGAAGAGGCTGGAGCTGGTGGCCGCCATCAACAGCGACGGCGGCATCACCTACTACCTGGACACCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACACCCTGTACCTGCAGATGAGCAGCCTGAAGAGCGAGGACACCGCCCTGTTCTACTGCGCCAGGCACAGGAGCGGCTACTTCAGCATGGACTACTGGGGCCAGGGCACCAGCGTGACCGTGAGCAGC
P01274_F01	glembatumumab	CAGGTGCAGCTGCAGGAGAGCGGCCCCGGCCTGGTGAAGCCCAGCCAGACCCTGAGCCTGACCTGCACCGTGAGCGGCGGCAGCATCAGCAGCTTCAACTACTACTGGAGCTGGATCAGGCACCACCCCGGCAAGGGCCTGGAGTGGATCGGCTACATCTACTACAGCGGCAGCACCTACAGCAACCCCAGCCTGAAGAGCAGGGTGACCATCAGCGTGGACACCAGCAAGAACCAGTTCAGCCTGACCCTGAGCAGCGTGACCGCCGCCGACACCGCCGTGTACTACTGCGCCAGGGGCTACAACTGGAACTACTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P01274_F09	ixekizumab	CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCAGCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCTACAGCTTCACCGACTACCACATCCACTGGGTGAGGCAGGCCCCCGGCCAGGGCCTGGAGTGGATGGGCGTGATCAACCCCATGTACGGCACCACCGACTACAACCAGAGGTTCAAGGGCAGGGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGTACGACTACTTCACCGGCACCGGCGTGTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P01274_F12	lenzilumab	CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCTACAGCTTCACCAACTACTACATCCACTGGGTGAGGCAGGCCCCCGGCCAGAGGCTGGAGTGGATGGGCTGGATCAACGCCGGCAACGGCAACACCAAGTACAGCCAGAAGTTCCAGGGCAGGGTGACCATCACCAGGGACACCAGCGCCAGCACCGCCTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGTGAGGAGGCAGAGGTTCCCCTACTACTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P01274_G06	mepolizumab	CAGGTGACCCTGAGGGAGAGCGGCCCCGCCCTGGTGAAGCCCACCCAGACCCTGACCCTGACCTGCACCGTGAGCGGCTTCAGCCTGACCAGCTACAGCGTGCACTGGGTGAGGCAGCCCCCCGGCAAGGGCCTGGAGTGGCTGGGCGTGATCTGGGCCAGCGGCGGCACCGACTACAACAGCGCCCTGATGAGCAGGCTGAGCATCAGCAAGGACACCAGCAGGAACCAGGTGGTGCTGACCATGACCAACATGGACCCCGTGGACACCGCCACCTACTACTGCGCCAGGGACCCCCCCAGCAGCCTGCTGAGGCTGGACTACTGGGGCAGGGGCACCCCCGTGACCGTGAGCAGC
P01274_G07	mogamulizumab	GAGGTGCAGCTGGTGGAGAGCGGCGGCGACCTGGTGCAGCCCGGCAGGAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCATCTTCAGCAACTACGGCATGAGCTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGGCCACCATCAGCAGCGCCAGCACCTACAGCTACTACCCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACAGCCTGTACCTGCAGATGAACAGCCTGAGGGTGGAGGACACCGCCCTGTACTACTGCGGCAGGCACAGCGACGGCAACTTCGCCTTCGGCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P01274_G09	muromonab	CAGGTGCAGCTGCAGCAGAGCGGCGCCGAGCTGGCCAGGCCCGGCGCCAGCGTGAAGATGAGCTGCAAGGCCAGCGGCTACACCTTCACCAGGTACACCATGCACTGGGTGAAGCAGAGGCCCGGCCAGGGCCTGGAGTGGATCGGCTACATCAACCCCAGCAGGGGCTACACCAACTACAACCAGAAGTTCAAGGACAAGGCCACCCTGACCACCGACAAGAGCAGCAGCACCGCCTACATGCAGCTGAGCAGCCTGACCAGCGAGGACAGCGCCGTGTACTACTGCGCCAGGTACTACGACGACCACTACTGCCTGGACTACTGGGGCCAGGGCACCACCCTGACCGTGAGCAGC
P01274_H02	obinutuzumab	CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCAGCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCTACGCCTTCAGCTACAGCTGGATCAACTGGGTGAGGCAGGCCCCCGGCCAGGGCCTGGAGTGGATGGGCAGGATCTTCCCCGGCGACGGCGACACCGACTACAACGGCAAGTTCAAGGGCAGGGTGACCATCACCGCCGACAAGAGCACCAGCACCGCCTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGAACGTGTTCGACGGCTACTGGCTGGTGTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P01274_H08	onartuzumab	GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTACACCTTCACCAGCTACTGGCTGCACTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGGGCATGATCGACCCCAGCAACAGCGACACCAGGTTCAACCCCAACTTCAAGGACAGGTTCACCATCAGCGCCGACACCAGCAAGAACACCGCCTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCACCTACAGGAGCTACGTGACCCCCCTGGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P01274_H09	otelixizumab	GAGGTGCAGCTGCTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCACCTTCAGCAGCTTCCCCATGGCCTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGAGCACCATCAGCACCAGCGGCGGCAGGACCTACTACAGGGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAAGTTCAGGCAGTACAGCGGCGGCTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P00483_A01	panitumumab	CAGGTGCAGCTGCAGGAGAGCGGCCCCGGCCTGGTGAAGCCCAGCGAGACCCTGAGCCTGACCTGCACCGTGAGCGGCGGCAGCGTGAGCAGCGGCGACTACTACTGGACCTGGATCAGGCAGAGCCCCGGCAAGGGCCTGGAGTGGATCGGCCACATCTACTACAGCGGCAACACCAACTACAACCCCAGCCTGAAGAGCAGGCTGACCATCAGCATCGACACCAGCAAGACCCAGTTCAGCCTGAAGCTGAGCAGCGTGACCGCCGCCGACACCGCCATCTACTACTGCGTGAGGGACAGGGTGACCGGCGCCTTCGACATCTGGGGCCAGGGCACCATGGTGACCGTGAGCAGC
P00483_A06	pertuzumab	GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCACCTTCACCGACTACACCATGGACTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGGCCGACGTGAACCCCAACAGCGGCGGCAGCATCTACAACCAGAGGTTCAAGGGCAGGTTCACCCTGAGCGTGGACAGGAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGAACCTGGGCCCCAGCTTCTACTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P00483_B08	seribantumab	GAGGTGCAGCTGCTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCACCTTCAGCCACTACGTGATGGCCTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGAGCAGCATCAGCAGCAGCGGCGGCTGGACCCTGTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCACCAGGGGCCTGAAGATGGCCACCATCTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P00483_B10	siltuximab	GAGGTGCAGCTGGTGGAGAGCGGCGGCAAGCTGCTGAAGCCCGGCGGCAGCCTGAAGCTGAGCTGCGCCGCCAGCGGCTTCACCTTCAGCAGCTTCGCCATGAGCTGGTTCAGGCAGAGCCCCGAGAAGAGGCTGGAGTGGGTGGCCGAGATCAGCAGCGGCGGCAGCTACACCTACTACCCCGACACCGTGACCGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACACCCTGTACCTGGAGATGAGCAGCCTGAGGAGCGAGGACACCGCCATGTACTACTGCGCCAGGGGCCTGTGGGGCTACTACGCCCTGGACTACTGGGGCCAGGGCACCAGCGTGACCGTGAGCAGC
P00483_B12	sirukumab	GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCACCTTCAGCCCCTTCGCCATGAGCTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGGCCAAGATCAGCCCCGGCGGCAGCTGGACCTACTACAGCGACACCGTGACCGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACAGCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGCAGCTGTGGGGCTACTACGCCCTGGACATCTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
P00483_C03	teplizumab	CAGGTGCAGCTGGTGCAGAGCGGCGGCGGCGTGGTGCAGCCCGGCAGGAGCCTGAGGCTGAGCTGCAAGGCCAGCGGCTACACCTTCACCAGGTACACCATGCACTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGATCGGCTACATCAACCCCAGCAGGGGCTACACCAACTACAACCAGAAGGTGAAGGACAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCGCCTTCCTGCAGATGGACAGCCTGAGGCCCGAGGACACCGGCGTGTACTTCTGCGCCAGGTACTACGACGACCACTACTGCCTGGACTACTGGGGCCAGGGCACCCCCGTGACCGTGAGCAGC
P00483_C04	tigatuzumab	GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCACCTTCAGCAGCTACGTGATGAGCTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGGCCACCATCAGCAGCGGCGGCAGCTACACCTACTACCCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACACCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGAGGGGCGACAGCATGATCACCACCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P00483_C06	tocilizumab	CAGGTGCAGCTGCAGGAGAGCGGCCCCGGCCTGGTGAGGCCCAGCCAGACCCTGAGCCTGACCTGCACCGTGAGCGGCTACAGCATCACCAGCGACCACGCCTGGAGCTGGGTGAGGCAGCCCCCCGGCAGGGGCCTGGAGTGGATCGGCTACATCAGCTACAGCGGCATCACCACCTACAACCCCAGCCTGAAGAGCAGGGTGACCATGCTGAGGGACACCAGCAAGAACCAGTTCAGCCTGAGGCTGAGCAGCGTGACCGCCGCCGACACCGCCGTGTACTACTGCGCCAGGAGCCTGGCCAGGACCACCGCCATGGACTACTGGGGCCAGGGCAGCCTGGTGACCGTGAGCAGC
P00483_C12	ustekinumab	GAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGAGAGCCTGAAGATCAGCTGCAAGGGCAGCGGCTACAGCTTCACCACCTACTGGCTGGGCTGGGTGAGGCAGATGCCCGGCAAGGGCCTGGACTGGATCGGCATCATGAGCCCCGTGGACAGCGACATCAGGTACAGCCCCAGCTTCCAGGGCCAGGTGACCATGAGCGTGGACAAGAGCATCACCACCGCCTACCTGCAGTGGAACAGCCTGAAGGCCAGCGACACCGCCATGTACTACTGCGCCAGGAGGAGGCCCGGCCAGGGCTACTTCGACTTCTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P00125_A10	bavituximab	GAGGTGCAGCTGCAGCAGAGCGGCCCCGAGCTGGAGAAGCCCGGCGCCAGCGTGAAGCTGAGCTGCAAGGCCAGCGGCTACAGCTTCACCGGCTACAACATGAACTGGGTGAAGCAGAGCCACGGCAAGAGCCTGGAGTGGATCGGCCACATCGACCCCTACTACGGCGACACCAGCTACAACCAGAAGTTCAGGGGCAAGGCCACCCTGACCGTGGACAAGAGCAGCAGCACCGCCTACATGCAGCTGAAGAGCCTGACCAGCGAGGACAGCGCCGTGTACTACTGCGTGAAGGGCGGCTACTACGGCCACTGGTACTTCGACGTGTGGGGCGCCGGCACCACCGTGACCGTGAGCAGC
P00863_C01	clazakizumab	GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCAGCCTGAGCAACTACTACGTGACCTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGGGCATCATCTACGGCAGCGACGAGACCGCCTACGCCACCAGCGCCATCGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGGACGACAGCAGCGACTGGGACGCCAAGTTCAACCTGTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P01274_E05	fresolimumab	CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCAGCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCTACACCTTCAGCAGCAACGTGATCAGCTGGGTGAGGCAGGCCCCCGGCCAGGGCCTGGAGTGGATGGGCGGCGTGATCCCCATCGTGGACATCGCCAACTACGCCCAGAGGTTCAAGGGCAGGGTGACCATCACCGCCGACGAGAGCACCAGCACCACCTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGCACCCTGGGCCTGGTGCTGGACGCCATGGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P01274_E11	gevokizumab	CAGGTGCAGCTGCAGGAGAGCGGCCCCGGCCTGGTGAAGCCCAGCCAGACCCTGAGCCTGACCTGCAGCTTCAGCGGCTTCAGCCTGAGCACCAGCGGCATGGGCGTGGGCTGGATCAGGCAGCCCAGCGGCAAGGGCCTGGAGTGGCTGGCCCACATCTGGTGGGACGGCGACGAGAGCTACAACCCCAGCCTGAAGAGCAGGCTGACCATCAGCAAGGACACCAGCAAGAACCAGGTGAGCCTGAAGATCACCAGCGTGACCGCCGCCGACACCGCCGTGTACTTCTGCGCCAGGAACAGGTACGACCCCCCCTGGTTCGTGGACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P01274_F05	imgatuzumab	CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCAGCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCTTCACCTTCACCGACTACAAGATCCACTGGGTGAGGCAGGCCCCCGGCCAGGGCCTGGAGTGGATGGGCTACTTCAACCCCAACAGCGGCTACAGCACCTACGCCCAGAAGTTCCAGGGCAGGGTGACCATCACCGCCGACAAGAGCACCAGCACCGCCTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGCTGAGCCCCGGCGGCTACTACGTGATGGACGCCTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
P01274_F06	infliximab	GAGGTGAAGCTGGAGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCATGAAGCTGAGCTGCGTGGCCAGCGGCTTCATCTTCAGCAACCACTGGATGAACTGGGTGAGGCAGAGCCCCGAGAAGGGCCTGGAGTGGGTGGCCGAGATCAGGAGCAAGAGCATCAACAGCGCCACCCACTACGCCGAGAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACGACAGCAAGAGCGCCGTGTACCTGCAGATGACCGACCTGAGGACCGAGGACACCGGCGTGTACTACTGCAGCAGGAACTACTACGGCAGCACCTACGACTACTGGGGCCAGGGCACCACCCTGACCGTGAGCAGC
P01274_G05	mavrilimumab	CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTGAGCTGCAAGGTGAGCGGCTACACCCTGACCGAGCTGAGCATCCACTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGATGGGCGGCTTCGACCCCGAGGAGAACGAGATCGTGTACGCCCAGAGGTTCCAGGGCAGGGTGACCATGACCGAGGACACCAGCACCGACACCGCCTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCATCGTGGGCAGCTTCAGCCCCCTGACCCTGGGCCTGTGGGGCCAGGGCACCATGGTGACCGTGAGCAGC
P01274_G08	motavizumab	CAGGTGACCCTGAGGGAGAGCGGCCCCGCCCTGGTGAAGCCCACCCAGACCCTGACCCTGACCTGCACCTTCAGCGGCTTCAGCCTGAGCACCGCCGGCATGAGCGTGGGCTGGATCAGGCAGCCCCCCGGCAAGGCCCTGGAGTGGCTGGCCGACATCTGGTGGGACGACAAGAAGCACTACAACCCCAGCCTGAAGGACAGGCTGACCATCAGCAAGGACACCAGCAAGAACCAGGTGGTGCTGAAGGTGACCAACATGGACCCCGCCGACACCGCCACCTACTACTGCGCCAGGGACATGATCTTCAACTTCTACTTCGACGTGTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
P01274_H06	olokizumab	GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCAACTTCAACGACTACTTCATGAACTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGGCCCAGATGAGGAACAAGAACTACCAGTACGGCACCTACTACGCCGAGAGCCTGGAGGGCAGGTTCACCATCAGCAGGGACGACAGCAAGAACAGCCTGTACCTGCAGATGAACAGCCTGAAGACCGAGGACACCGCCGTGTACTACTGCGCCAGGGAGAGCTACTACGGCTTCACCAGCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P01274_H12	palivizumab	CAGGTGACCCTGAGGGAGAGCGGCCCCGCCCTGGTGAAGCCCACCCAGACCCTGACCCTGACCTGCACCTTCAGCGGCTTCAGCCTGAGCACCAGCGGCATGAGCGTGGGCTGGATCAGGCAGCCCCCCGGCAAGGCCCTGGAGTGGCTGGCCGACATCTGGTGGGACGACAAGAAGGACTACAACCCCAGCCTGAAGAGCAGGCTGACCATCAGCAAGGACACCAGCAAGAACCAGGTGGTGCTGAAGGTGACCAACATGGACCCCGCCGACACCGCCACCTACTACTGCGCCAGGAGCATGATCACCAACTGGTACTTCGACGTGTGGGGCGCCGGCACCACCGTGACCGTGAGCAGC
P00483_A05	pembrolizumab	CAGGTGCAGCTGGTGCAGAGCGGCGTGGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCTACACCTTCACCAACTACTACATGTACTGGGTGAGGCAGGCCCCCGGCCAGGGCCTGGAGTGGATGGGCGGCATCAACCCCAGCAACGGCGGCACCAACTTCAACGAGAAGTTCAAGAACAGGGTGACCCTGACCACCGACAGCAGCACCACCACCGCCTACATGGAGCTGAAGAGCCTGCAGTTCGACGACACCGCCGTGTACTACTGCGCCAGGAGGGACTACAGGTTCGACATGGGCTTCGACTACTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
P00483_A07	pinatuzumab	GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTACGAGTTCAGCAGGAGCTGGATGAACTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGGGCAGGATCTACCCCGGCGACGGCGACACCAACTACAGCGGCAAGTTCAAGGGCAGGTTCACCATCAGCGCCGACACCAGCAAGAACACCGCCTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGGACGGCAGCAGCTGGGACTGGTACTTCGACGTGTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P00483_B02	rilotumumab	CAGGTGCAGCTGCAGGAGAGCGGCCCCGGCCTGGTGAAGCCCAGCGAGACCCTGAGCCTGACCTGCACCGTGAGCGGCGGCAGCATCAGCATCTACTACTGGAGCTGGATCAGGCAGCCCCCCGGCAAGGGCCTGGAGTGGATCGGCTACGTGTACTACAGCGGCAGCACCAACTACAACCCCAGCCTGAAGAGCAGGGTGACCATCAGCGTGGACACCAGCAAGAACCAGTTCAGCCTGAAGCTGAACAGCGTGACCGCCGCCGACACCGCCGTGTACTACTGCGCCAGGGGCGGCTACGACTTCTGGAGCGGCTACTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P00483_C07	tovetumab	CAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGAAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCACCTTCAGCGACTACTACATGAACTGGATCAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGAGCTACATCAGCAGCAGCGGCAGCATCATCTACTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACAGCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGGAGGGCAGGATCGCCGCCAGGGGCATGGACGTGTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
P00483_C09	trastuzumab	GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCAACATCAAGGACACCTACATCCACTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGGCCAGGATCTACCCCACCAACGGCTACACCAGGTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCGCCGACACCAGCAAGAACACCGCCTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCAGCAGGTGGGGCGGCGACGGCTTCTACGCCATGGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P00483_D03	visilizumab	CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCTACACCTTCATCAGCTACACCATGCACTGGGTGAGGCAGGCCCCCGGCCAGGGCCTGGAGTGGATGGGCTACATCAACCCCAGGAGCGGCTACACCCACTACAACCAGAAGCTGAAGGACAAGGCCACCCTGACCGCCGACAAGAGCGCCAGCACCGCCTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGAGCGCCTACTACGACTACGACGGCTTCGCCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P00125_A03	adalimumab	GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCAGGAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCACCTTCGACGACTACGCCATGCACTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGAGCGCCATCACCTGGAACAGCGGCCACATCGACTACGCCGACAGCGTGGAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACAGCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAAGGTGAGCTACCTGAGCACCGCCAGCAGCCTGGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P00125_A04	alemtuzumab	CAGGTGCAGCTGCAGGAGAGCGGCCCCGGCCTGGTGAGGCCCAGCCAGACCCTGAGCCTGACCTGCACCGTGAGCGGCTTCACCTTCACCGACTTCTACATGAACTGGGTGAGGCAGCCCCCCGGCAGGGGCCTGGAGTGGATCGGCTTCATCAGGGACAAGGCCAAGGGCTACACCACCGAGTACAACCCCAGCGTGAAGGGCAGGGTGACCATGCTGGTGGACACCAGCAAGAACCAGTTCAGCCTGAGGCTGAGCAGCGTGACCGCCGCCGACACCGCCGTGTACTACTGCGCCAGGGAGGGCCACACCGCCGCCCCCTTCGACTACTGGGGCCAGGGCAGCCTGGTGACCGTGAGCAGC
P00125_A12	benralizumab	GAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCTACACCTTCACCAGCTACGTGATCCACTGGGTGAGGCAGAGGCCCGGCCAGGGCCTGGCCTGGATGGGCTACATCAACCCCTACAACGACGGCACCAAGTACAACGAGAGGTTCAAGGGCAAGGTGACCATCACCAGCGACAGGAGCACCAGCACCGTGTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACCTGTGCGGCAGGGAGGGCATCAGGTACTACGGCCTGCTGGGCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P00863_C10	drozitumab	GAGGTGCAGCTGGTGCAGAGCGGCGGCGGCGTGGAGAGGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCACCTTCGACGACTACGCCATGAGCTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGAGCGGCATCAACTGGCAGGGCGGCAGCACCGGCTACGCCGACAGCGTGAAGGGCAGGGTGACCATCAGCAGGGACAACGCCAAGAACAGCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAAGATCCTGGGCGCCGGCAGGGGCTGGTACTTCGACTACTGGGGCAAGGGCACCACCGTGACCGTGAGCAGC
P00863_C11	duligotuzumab	GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCACCCTGAGCGGCGACTGGATCCACTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGGGCGAGATCAGCGCCGCCGGCGGCTACACCGACTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCGCCGACACCAGCAAGAACACCGCCTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGGAGAGCAGGGTGAGCTTCGAGGCCGCCATGGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P00863_D02	efalizumab	GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTACAGCTTCACCGGCCACTGGATGAACTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGGGCATGATCCACCCCAGCGACAGCGAGACCAGGTACAACCAGAAGTTCAAGGACAGGTTCACCATCAGCGTGGACAAGAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGGGCATCTACTTCTACGGCACCACCTACTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P01274_D12	fezakinumab	CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCTACACCTTCACCAACTACTACATGCACTGGGTGAGGCAGGCCCCCGGCCAGGGCCTGGAGTGGGTGGGCTGGATCAACCCCTACACCGGCAGCGCCTTCTACGCCCAGAAGTTCAGGGGCAGGGTGACCATGACCAGGGACACCAGCATCAGCACCGCCTACATGGAGCTGAGCAGGCTGAGGAGCGACGACACCGCCGTGTACTACTGCGCCAGGGAGCCCGAGAAGTTCGACAGCGACGACAGCGACGTGTGGGGCAGGGGCACCCTGGTGACCGTGAGCAGC
P01274_F07	inotuzumab	GAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCTACAGGTTCACCAACTACTGGATCCACTGGGTGAGGCAGGCCCCCGGCCAGGGCCTGGAGTGGATCGGCGGCATCAACCCCGGCAACAACTACGCCACCTACAGGAGGAAGTTCCAGGGCAGGGTGACCATGACCGCCGACACCAGCACCAGCACCGTGTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCACCAGGGAGGGCTACGGCAACTACGGCGCCTGGTTCGCCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P01274_G04	matuzumab	CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCTACACCTTCACCAGCCACTGGATGCACTGGGTGAGGCAGGCCCCCGGCCAGGGCCTGGAGTGGATCGGCGAGTTCAACCCCAGCAACGGCAGGACCAACTACAACGAGAAGTTCAAGAGCAAGGCCACCATGACCGTGGACACCAGCACCAACACCGCCTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGCAGGGACTACGACTACGACGGCAGGTACTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P01274_G11	necitumumab	CAGGTGCAGCTGCAGGAGAGCGGCCCCGGCCTGGTGAAGCCCAGCCAGACCCTGAGCCTGACCTGCACCGTGAGCGGCGGCAGCATCAGCAGCGGCGACTACTACTGGAGCTGGATCAGGCAGCCCCCCGGCAAGGGCCTGGAGTGGATCGGCTACATCTACTACAGCGGCAGCACCGACTACAACCCCAGCCTGAAGAGCAGGGTGACCATGAGCGTGGACACCAGCAAGAACCAGTTCAGCCTGAAGGTGAACAGCGTGACCGCCGCCGACACCGCCGTGTACTACTGCGCCAGGGTGAGCATCTTCGGCGTGGGCACCTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P01274_H07	omalizumab	GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGTGAGCGGCTACAGCATCACCAGCGGCTACAGCTGGAACTGGATCAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGGCCAGCATCACCTACGACGGCAGCACCAACTACAACCCCAGCCTGAAGGGCAGGATCACCATCAGCAGGGACGACAGCAAGAACACCTTCTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGGGCAGCCACTACTTCGGCCACTGGCACTTCGCCGTGTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P00483_B03	rituximab	CAGGTGCAGCTGCAGCAGCCCGGCGCCGAGCTGGTGAAGCCCGGCGCCAGCGTGAAGATGAGCTGCAAGGCCAGCGGCTACACCTTCACCAGCTACAACATGCACTGGGTGAAGCAGACCCCCGGCAGGGGCCTGGAGTGGATCGGCGCCATCTACCCCGGCAACGGCGACACCAGCTACAACCAGAAGTTCAAGGGCAAGGCCACCCTGACCGCCGACAAGAGCAGCAGCACCGCCTACATGCAGCTGAGCAGCCTGACCAGCGAGGACAGCGCCGTGTACTACTGCGCCAGGAGCACCTACTACGGCGGCGACTGGTACTTCAACGTGTGGGGCGCCGGCACCACCGTGACCGTGAGCGCC
P00483_C02	tanezumab	CAGGTGCAGCTGCAGGAGAGCGGCCCCGGCCTGGTGAAGCCCAGCGAGACCCTGAGCCTGACCTGCACCGTGAGCGGCTTCAGCCTGATCGGCTACGACCTGAACTGGATCAGGCAGCCCCCCGGCAAGGGCCTGGAGTGGATCGGCATCATCTGGGGCGACGGCACCACCGACTACAACAGCGCCGTGAAGAGCAGGGTGACCATCAGCAAGGACACCAGCAAGAACCAGTTCAGCCTGAAGCTGAGCAGCGTGACCGCCGCCGACACCGCCGTGTACTACTGCGCCAGGGGCGGCTACTGGTACGCCACCAGCTACTACTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P00483_C11	urelumab	CAGGTGCAGCTGCAGCAGTGGGGCGCCGGCCTGCTGAAGCCCAGCGAGACCCTGAGCCTGACCTGCGCCGTGTACGGCGGCAGCTTCAGCGGCTACTACTGGAGCTGGATCAGGCAGAGCCCCGAGAAGGGCCTGGAGTGGATCGGCGAGATCAACCACGGCGGCTACGTGACCTACAACCCCAGCCTGGAGAGCAGGGTGACCATCAGCGTGGACACCAGCAAGAACCAGTTCAGCCTGAAGCTGAGCAGCGTGACCGCCGCCGACACCGCCGTGTACTACTGCGCCAGGGACTACGGCCCCGGCAACTACGACTGGTACTTCGACCTGTGGGGCAGGGGCACCCTGGTGACCGTGAGCAGC
P00483_D01	vedolizumab	CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTGAGCTGCAAGGGCAGCGGCTACACCTTCACCAGCTACTGGATGCACTGGGTGAGGCAGGCCCCCGGCCAGAGGCTGGAGTGGATCGGCGAGATCGACCCCAGCGAGAGCAACACCAACTACAACCAGAAGTTCAAGGGCAGGGTGACCCTGACCGTGGACATCAGCGCCAGCACCGCCTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGGGCGGCTACGACGGCTGGGACTACGCCATCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P00483_D02	veltuzumab	CAGGTGCAGCTGCAGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCAGCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCTACACCTTCACCAGCTACAACATGCACTGGGTGAAGCAGGCCCCCGGCCAGGGCCTGGAGTGGATCGGCGCCATCTACCCCGGCATGGGCGACACCAGCTACAACCAGAAGTTCAAGGGCAAGGCCACCCTGACCGCCGACGAGAGCACCAACACCGCCTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCTTCTACTACTGCGCCAGGAGCACCTACTACGGCGGCGACTGGTACTTCGACGTGTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
P00863_C07	daratumumab	GAGGTGCAGCTGCTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGTGAGCGGCTTCACCTTCAACAGCTTCGCCATGAGCTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGAGCGCCATCAGCGGCAGCGGCGGCGGCACCTACTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTTCTGCGCCAAGGACAAGATCCTGTGGTTCGGCGAGCCCGTGTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P00863_C08	denosumab	GAGGTGCAGCTGCTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCACCTTCAGCAGCTACGCCATGAGCTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGAGCGGCATCACCGGCAGCGGCGGCAGCACCTACTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAAGGACCCCGGCACCACCGTGATCATGAGCTGGTTCGACCCCTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P00863_D01	eculizumab	CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCTACATCTTCAGCAACTACTGGATCCAGTGGGTGAGGCAGGCCCCCGGCCAGGGCCTGGAGTGGATGGGCGAGATCCTGCCCGGCAGCGGCAGCACCGAGTACACCGAGAACTTCAAGGACAGGGTGACCATGACCAGGGACACCAGCACCAGCACCGTGTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGTACTTCTTCGGCAGCAGCCCCAACTGGTACTTCGACGTGTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P01274_D06	enokizumab	CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCAGCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCGGCACCTTCAGCTACTACTGGATCGAGTGGGTGAGGCAGGCCCCCGGCCAGGGCCTGGAGTGGATGGGCGAGATCCTGCCCGGCAGCGGCACCACCAACCCCAACGAGAAGTTCAAGGGCAGGGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGGCCGACTACTACGGCAGCGACTACGTGAAGTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P01274_F04	ibalizumab	CAGGTGCAGCTGCAGCAGAGCGGCCCCGAGGTGGTGAAGCCCGGCGCCAGCGTGAAGATGAGCTGCAAGGCCAGCGGCTACACCTTCACCAGCTACGTGATCCACTGGGTGAGGCAGAAGCCCGGCCAGGGCCTGGACTGGATCGGCTACATCAACCCCTACAACGACGGCACCGACTACGACGAGAAGTTCAAGGGCAAGGCCACCCTGACCAGCGACACCAGCACCAGCACCGCCTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGGAGAAGGACAACTACGCCACCGGCGCCTGGTTCGCCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P01274_H03	ocrelizumab	GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTACACCTTCACCAGCTACAACATGCACTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGGGCGCCATCTACCCCGGCAACGGCGACACCAGCTACAACCAGAAGTTCAAGGGCAGGTTCACCATCAGCGTGGACAAGAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGGTGGTGTACTACAGCAACAGCTACTGGTACTTCGACGTGTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P01274_H04	ofatumumab	GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCAGGAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCACCTTCAACGACTACGCCATGCACTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGAGCACCATCAGCTGGAACAGCGGCAGCATCGGCTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAAGAGCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCCTGTACTACTGCGCCAAGGACATCCAGTACGGCAACTACTACTACGGCATGGACGTGTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
P00483_C08	tralokinumab	CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCTACACCTTCACCAACTACGGCCTGAGCTGGGTGAGGCAGGCCCCCGGCCAGGGCCTGGAGTGGATGGGCTGGATCAGCGCCAACAACGGCGACACCAACTACGGCCAGGAGTTCCAGGGCAGGGTGACCATGACCACCGACACCAGCACCAGCACCGCCTACATGGAGCTGAGGAGCCTGAGGAGCGACGACACCGCCGTGTACTACTGCGCCAGGGACAGCAGCAGCAGCTGGGCCAGGTGGTTCTTCGACCTGTGGGGCAGGGGCACCCTGGTGACCGTGAGCAGC
P00125_A11	belimumab	CAGGTGCAGCTGCAGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCAGCAGCGTGAGGGTGAGCTGCAAGGCCAGCGGCGGCACCTTCAACAACAACGCCATCAACTGGGTGAGGCAGGCCCCCGGCCAGGGCCTGGAGTGGATGGGCGGCATCATCCCCATGTTCGGCACCGCCAAGTACAGCCAGAACTTCCAGGGCAGGGTGGCCATCACCGCCGACGAGAGCACCGGCACCGCCAGCATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGAGCAGGGACCTGCTGCTGTTCCCCCACCACGCCCTGAGCCCCTGGGGCAGGGGCACCATGGTGACCGTGAGCAGC
P00125_B01	bevacizumab	GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTACACCTTCACCAACTACGGCATGAACTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGGGCTGGATCAACACCTACACCGGCGAGCCCACCTACGCCGCCGACTTCAAGAGGAGGTTCACCTTCAGCCTGGACACCAGCAAGAGCACCGCCTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAAGTACCCCCACTACTACGGCAGCAGCCACTGGTACTTCGACGTGTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P01274_E06	fulranumab	GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCACCCTGAGGAGCTACAGCATGAACTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGAGCTACATCAGCAGGAGCAGCCACACCATCTTCTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACAGCCTGTACCTGCAGATGGACAGCCTGAGGGACGAGGACACCGCCATGTACTACTGCGCCAGGGTGTACAGCAGCGGCTGGCACGTGAGCGACTACTTCGACTACTGGGGCCAGGGCATCCTGGTGACCGTGAGCAGC
P01274_G02	lirilumab	CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCAGCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCGGCACCTTCAGCTTCTACGCCATCAGCTGGGTGAGGCAGGCCCCCGGCCAGGGCCTGGAGTGGATGGGCGGCTTCATCCCCATCTTCGGCGCCGCCAACTACGCCCAGAAGTTCCAGGGCAGGGTGACCATCACCGCCGACGAGAGCACCAGCACCGCCTACATGGAGCTGAGCAGCCTGAGGAGCGACGACACCGCCGTGTACTACTGCGCCAGGATCCCCAGCGGCAGCTACTACTACGACTACGACATGGACGTGTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
P01274_G10	natalizumab	CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCTTCAACATCAAGGACACCTACATCCACTGGGTGAGGCAGGCCCCCGGCCAGAGGCTGGAGTGGATGGGCAGGATCGACCCCGCCAACGGCTACACCAAGTACGACCCCAAGTTCCAGGGCAGGGTGACCATCACCGCCGACACCAGCGCCAGCACCGCCTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGGAGGGCTACTACGGCAACTACGGCGTGTACGCCATGGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P01274_G12	nimotuzumab	CAGGTGCAGCTGCAGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCAGCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCTACACCTTCACCAACTACTACATCTACTGGGTGAGGCAGGCCCCCGGCCAGGGCCTGGAGTGGATCGGCGGCATCAACCCCACCAGCGGCGGCAGCAACTTCAACGAGAAGTTCAAGACCAGGGTGACCATCACCGCCGACGAGAGCAGCACCACCGCCTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCTTCTACTTCTGCACCAGGCAGGGCCTGTGGTTCGACAGCGACGGCAGGGGCTTCGACTTCTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
P00483_A03	parsatuzumab	GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTACACCTTCATCGACTACTACATGAACTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGGGCGACATCAACCTGGACAACAGCGGCACCCACTACAACCAGAAGTTCAAGGGCAGGTTCACCATCAGCAGGGACAAGAGCAAGAACACCGCCTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGGAGGGCGTGTACCACGACTACGACGACTACGCCATGGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P00483_A12	ranibizumab	GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTACGACTTCACCCACTACGGCATGAACTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGGGCTGGATCAACACCTACACCGGCGAGCCCACCTACGCCGCCGACTTCAAGAGGAGGTTCACCTTCAGCCTGGACACCAGCAAGAGCACCGCCTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAAGTACCCCTACTACTACGGCACCAGCCACTGGTACTTCGACGTGTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P00483_B05	romosozumab	GAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGCCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCTACACCTTCACCGACTACAACATGCACTGGGTGAGGCAGGCCCCCGGCCAGGGCCTGGAGTGGATGGGCGAGATCAACCCCAACAGCGGCGGCGCCGGCTACAACCAGAAGTTCAAGGGCAGGGTGACCATGACCACCGACACCAGCACCAGCACCGCCTACATGGAGCTGAGGAGCCTGAGGAGCGACGACACCGCCGTGTACTACTGCGCCAGGCTGGGCTACGACGACATCTACGACGACTGGTACTTCGACGTGTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
P00483_C01	tabalumab	CAGGTGCAGCTGCAGCAGTGGGGCGCCGGCCTGCTGAAGCCCAGCGAGACCCTGAGCCTGACCTGCGCCGTGTACGGCGGCAGCTTCAGCGGCTACTACTGGAGCTGGATCAGGCAGCCCCCCGGCAAGGGCCTGGAGTGGATCGGCGAGATCAACCACAGCGGCAGCACCAACTACAACCCCAGCCTGAAGAGCAGGGTGACCATCAGCGTGGACACCAGCAAGAACCAGTTCAGCCTGAAGCTGAGCAGCGTGACCGCCGCCGACACCGCCGTGTACTACTGCGCCAGGGGCTACTACGACATCCTGACCGGCTACTACTACTACTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P01274_D03	eldelumab	CAGATGCAGCTGGTGGAGAGCGGCGGCGGCGTGGTGCAGCCCGGCAGGAGCCTGAGGCTGAGCTGCACCGCCAGCGGCTTCACCTTCAGCAACAACGGCATGCACTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGGCCGTGATCTGGTTCGACGGCATGAACAAGTTCTACGTGGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTACCTGGAGATGAACAGCCTGAGGGCCGAGGACACCGCCATCTACTACTGCGCCAGGGAGGGCGACGGCAGCGGCATCTACTACTACTACGGCATGGACGTGTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
P00863_C12	dupilumab	GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGAGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGGCAGCGGCTTCACCTTCAGGGACTACGCCATGACCTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGAGCAGCATCAGCGGCAGCGGCGGCAACACCTACTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAAGGACAGGCTGAGCATCACCATCAGGCCCAGGTACTACGGCCTGGACGTGTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
P01274_E02	figitumumab	GAGGTGCAGCTGCTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCACCGCCAGCGGCTTCACCTTCAGCAGCTACGCCATGAACTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGAGCGCCATCAGCGGCAGCGGCGGCACCACCTTCTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAGGACCACCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAAGGACCTGGGCTGGAGCGACAGCTACTACTACTACTACGGCATGGACGTGTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
P00483_C10	tremelimumab	CAGGTGCAGCTGGTGGAGAGCGGCGGCGGCGTGGTGCAGCCCGGCAGGAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCACCTTCAGCAGCTACGGCATGCACTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGGCCGTGATCTGGTACGACGGCAGCAACAAGTACTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGGACCCCAGGGGCGCCACCCTGTACTACTACTACTACGGCATGGACGTGTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
P00483_D04	zalutumumab	CAGGTGCAGCTGGTGGAGAGCGGCGGCGGCGTGGTGCAGCCCGGCAGGAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCACCTTCAGCACCTACGGCATGCACTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGGCCGTGATCTGGGACGACGGCAGCTACAAGTACTACGGCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGGACGGCATCACCATGGTGAGGGGCGTGATGAAGGACTACTTCGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P01274_E09	gantenerumab	CAGGTGGAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCACCTTCAGCAGCTACGCCATGAGCTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGAGCGCCATCAACGCCAGCGGCACCAGGACCTACTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGGGCAAGGGCAACACCCACAAGCCCTACGGCTACGTGAGGTACTTCGACGTGTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGC
P01274_F02	golimumab	CAGGTGCAGCTGGTGGAGAGCGGCGGCGGCGTGGTGCAGCCCGGCAGGAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCATCTTCAGCAGCTACGCCATGCACTGGGTGAGGCAGGCCCCCGGCAACGGCCTGGAGTGGGTGGCCTTCATGAGCTACGACGGCAGCAACAAGAAGTACGCCGACAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGGACAGGGGCATCGCCGCCGGCGGCAACTACTACTACTACGGCATGGACGTGTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
P01274_E03	fletikumab	CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAGGCCCGGCGCCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCTACACCTTCACCAACGACATCATCCACTGGGTGAGGCAGGCCCCCGGCCAGAGGCTGGAGTGGATGGGCTGGATCAACGCCGGCTACGGCAACACCCAGTACAGCCAGAACTTCCAGGACAGGGTGAGCATCACCAGGGACACCAGCGCCAGCACCGCCTACATGGAGCTGATCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGGAGCCCCTGTGGTTCGGCGAGAGCAGCCCCCACGACTACTACGGCATGGACGTGTGGGGCCAGGGCACCACCGTGACCGTGAGCAGC
P01274_E07	galiximab	CAGGTGCAGCTGCAGGAGAGCGGCCCCGGCCTGGTGAAGCCCAGCGAGACCCTGAGCCTGACCTGCGCCGTGAGCGGCGGCAGCATCAGCGGCGGCTACGGCTGGGGCTGGATCAGGCAGCCCCCCGGCAAGGGCCTGGAGTGGATCGGCAGCTTCTACAGCAGCAGCGGCAACACCTACTACAACCCCAGCCTGAAGAGCCAGGTGACCATCAGCACCGACACCAGCAAGAACCAGTTCAGCCTGAAGCTGAACAGCATGACCGCCGCCGACACCGCCGTGTACTACTGCGTGAGGGACAGGCTGTTCAGCGTGGTGGGCATGGTGTACAACAACTGGTTCGACGTGTGGGGCCCCGGCGTGCTGGTGACCGTGAGCAGC
P01274_H05	olaratumab	CAGCTGCAGCTGCAGGAGAGCGGCCCCGGCCTGGTGAAGCCCAGCGAGACCCTGAGCCTGACCTGCACCGTGAGCGGCGGCAGCATCAACAGCAGCAGCTACTACTGGGGCTGGCTGAGGCAGAGCCCCGGCAAGGGCCTGGAGTGGATCGGCAGCTTCTTCTACACCGGCAGCACCTACTACAACCCCAGCCTGAGGAGCAGGCTGACCATCAGCGTGGACACCAGCAAGAACCAGTTCAGCCTGATGCTGAGCAGCGTGACCGCCGCCGACACCGCCGTGTACTACTGCGCCAGGCAGAGCACCTACTACTACGGCAGCGGCAACTACTACGGCTGGTTCGACAGGTGGGACCAGGGCACCCTGGTGACCGTGAGCAGC
P00483_B07	secukinumab	GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCGCCGCCAGCGGCTTCACCTTCAGCAACTACTGGATGAACTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGGCCGCCATCAACCAGGACGGCAGCGAGAAGTACTACGTGGGCAGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACAGCCTGTACCTGCAGATGAACAGCCTGAGGGTGGAGGACACCGCCGTGTACTACTGCGTGAGGGACTACTACGACATCCTGACCGACTACTACATCCACTACTGGTACTTCGACCTGTGGGGCAGGGGCACCCTGGTGACCGTGAGCAGC
P00863_B12	cixutumumab	GAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCAGCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCGGCACCTTCAGCAGCTACGCCATCAGCTGGGTGAGGCAGGCCCCCGGCCAGGGCCTGGAGTGGATGGGCGGCATCATCCCCATCTTCGGCACCGCCAACTACGCCCAGAAGTTCCAGGGCAGGGTGACCATCACCGCCGACAAGAGCACCAGCACCGCCTACATGGAGCTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGGCCCCCCTGAGGTTCCTGGAGTGGAGCACCCAGGACCACTACTACTACTACTACATGGACGTGTGGGGCAAGGGCACCACCGTGACCGTGAGCAGC